LYM
MCID: LYM017
MIFTS: 64

Lyme Disease (LYM)

Categories: Infectious diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lyme Disease

MalaCards integrated aliases for Lyme Disease:

Name: Lyme Disease 12 75 53 25 59 55 43 3 44 15 17 72 33
Lyme Borreliosis 12 53 25 59 15
Lyme Neuroborreliosis 12 55 44 72
Borrelia Burgdorferi Infection 25 3
Neuroborreliosis 12 72
Borreliosis 53 55
Infection Due to Borrelia Burgdorferi Sensu Lato 25
Infection by Borrelia Burgdorferi 25
Neurological Lyme Disease 12
B. Burgdorferi Infection 25
Bannworth's Syndrome 12
Borrelia Infections 72
Bannwarth Syndrome 12
Borreliosis, Lyme 25
Lym 75

Characteristics:

Orphanet epidemiological data:

59
lyme disease
Inheritance: Not applicable; Prevalence: >1/1000 (Europe),1-5/10000 (France); Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:11729
ICD9CM 35 088.81
NCIt 50 C45161
SNOMED-CT 68 23502006 48982009
ICD10 33 A69.2 A69.20
MESH via Orphanet 45 D008193
ICD10 via Orphanet 34 A69.2
UMLS via Orphanet 73 C0024198
Orphanet 59 ORPHA91546
UMLS 72 C0006035 C0024198 C0752235 more

Summaries for Lyme Disease

Genetics Home Reference : 25 Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. The bacteria are transferred to humans by tick bite, specifically by blacklegged ticks (commonly known as deer ticks). The condition is named for the location in which it was first described, the town of Lyme, Connecticut. Borrelia burgdorferi If not treated with antibiotics, Lyme disease follows three stages: early localized, early disseminated, and late disseminated infection. A small percentage of individuals have symptoms that persist months or years after treatment, which is called post-treatment Lyme disease syndrome. A characteristic feature of Lyme disease, and the key feature of early localized infection, is a slowly expanding red rash on the skin (called erythema migrans) at the site of the tick bite; the rash is often bull's-eye shaped. Flu-like symptoms and enlarged lymph nodes (lymphadenopathy) are also early signs of infection. Most people who are treated at this stage never develop further symptoms. The early disseminated stage of Lyme disease occurs as the bacteria is carried throughout the body in the bloodstream. This stage occurs a few weeks after the tick bite. Signs and symptoms can include additional rashes on other parts of the body, flu-like symptoms, and lymphadenopathy. Some affected individuals develop neurologic problems (referred to as neuroborreliosis), such as paralyzed muscles in the face (facial palsy); pain, numbness, or weakness in the hands or feet; difficulty concentrating; or memory problems. Rarely, the heart is affected (Lyme carditis), causing a sensation of fluttering or pounding in the chest (palpitations) or an irregular heartbeat. The late disseminated stage of Lyme disease can occur months to years after the tick bite. The most common feature of this stage, Lyme arthritis, is characterized by episodes of joint pain and swelling, usually affecting the knees. In rare cases, the late disseminated stage also involves neurological problems. Individuals with post-treatment Lyme disease syndrome report ongoing exhaustion (fatigue), muscle and joint achiness, headache, or difficulty concentrating even after treatment with antibiotics, when there is no evidence of the bacteria in the body. Very rarely, individuals have joint pain and swelling for months or years after successful antibiotic treatment. This complication is called antibiotic-refractory Lyme arthritis.

MalaCards based summary : Lyme Disease, also known as lyme borreliosis, is related to neurosyphilis and myocarditis, and has symptoms including fever, fatigue and headache. An important gene associated with Lyme Disease is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Ceftriaxone and Penicillin V have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and heart, and related phenotypes are arthritis and cranial nerve paralysis

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, has material basis in Borrelia burgdorferi, which is transmitted by blacklegged tick (Ixodes scapularis) or transmitted by western blacklegged tick (Ixodes pacificus). The infection has symptom fever, has symptom headache, has symptom fatigue, and has symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.

NIH Rare Diseases : 53 Lyme disease is the most common tickborne infectious disease in the United States. Early signs and symptoms of the condition include fever, chills, muscle pain, headache, and joint pain. As the condition progresses, affected people may experience heart problems, Bell's palsy, arthritis, abnormal muscle movement, speech problems and cognitive (thinking) abnormalities. Please visit the Center for Disease Control and Prevention's Web site for a more comprehensive list of symptoms. Lyme disease is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of infected blacklegged ticks. Certain features of the condition, including whether or not an affected person will develop medication-resistant chronic arthritis, is thought to be influenced by genetic factors (certain human leukocyte antigen genes). Treatment generally includes antibiotics to address the bacterial infection and other medications (i.e. pain medications) to relieve symptoms.

MedlinePlus : 43 Lyme disease is a bacterial infection you get from the bite of an infected tick. The first symptom is usually a red rash, which may look like a bull's eye. But not all people with Lyme disease have a rash. As the infection spreads to other parts of the body, you may have A fever A headache Body aches A stiff neck Fatigue Lyme disease can be hard to diagnose because many of its symptoms are like those of the flu and other diseases. And you may not have noticed a tick bite. Your health care provider will look at your symptoms and medical history to figure out whether you have Lyme disease. Lab tests may not always give a clear answer until you have been infected for at least a few weeks. Antibiotics can cure most cases of Lyme disease. The sooner treatment begins, the quicker and more complete the recovery. After treatment, some patients may still have muscle or joint aches and nervous system symptoms. This is called post-treatment Lyme disease syndrome (PTLDS). Long-term antibiotics have not been shown to help with PTLDS. However, there are ways to help with the symptoms of PTLDS, and most patients do get better with time.

CDC : 3 Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Wikipedia : 75 Lyme disease, also known as Lyme borreliosis, is an infectious disease caused by a bacterium named... more...

Related Diseases for Lyme Disease

Diseases related to Lyme Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 800)
# Related Disease Score Top Affiliating Genes
1 neurosyphilis 30.7 TLR6 TLR2 TLR1
2 myocarditis 30.7 TNF IL6 CD40LG
3 exanthem 30.6 TNF TLR9 IL6
4 urethritis 30.6 TLR6 TLR1 HSPD1
5 proliferative glomerulonephritis 30.6 IL6 CFH C3
6 leprosy 3 30.5 TNF TLR2 HSPD1
7 chronic fatigue syndrome 30.4 TNF IL6 IL1B
8 choroiditis 30.3 TNF CFH
9 prosthetic joint infection 30.3 TLR2 IL1B
10 meningoencephalitis 30.3 TLR9 IL6 CD40LG
11 posterior uveitis 30.3 TNF IL6 CFH
12 juvenile rheumatoid arthritis 30.2 TNF IL6 IL1B
13 synovitis 30.2 TNF IL6 IL1B
14 pericarditis 30.2 TNF IL6 IL1B
15 keratitis, hereditary 30.1 TLR9 TLR2 IL1B
16 multifocal choroiditis 30.1 TNF CFH
17 legionellosis 30.1 TNF TLR2 IL1B
18 membranoproliferative glomerulonephritis 30.0 CFH C4A C3
19 louse-borne relapsing fever 30.0 TNF IL6 CFHR1
20 eales disease 29.9 TNF IL6 IL1B
21 complex regional pain syndrome 29.9 TNF IL6 IL1B
22 endocarditis 29.9 TNF TLR2 IL6 HSPD1
23 infective endocarditis 29.8 TNF TLR2 IL6
24 haemophilus influenzae 29.8 TNF TLR2 IL1B CFH
25 peripheral nervous system disease 29.8 TNF TLR9 IL6
26 pertussis 29.7 TNF IL6 IL1B
27 proteasome-associated autoinflammatory syndrome 1 29.7 TNF TLR2 IL6 IL1B
28 scrub typhus 29.7 TNF TLR2 IL1B
29 brucellosis 29.7 TNF IL6 CD40LG
30 cytomegalovirus infection 29.7 TNF IL6 IL1B
31 leptospirosis 29.6 TNF TLR2 TLR1 IL6 IL1B
32 acquired immunodeficiency syndrome 29.6 TNF IL6 IL1B
33 otitis media 29.6 TNF TLR2 IL6 IL1B
34 demyelinating disease 29.6 TNF IL1B CD40LG
35 adult-onset still's disease 29.5 TNF IL6 IL1B
36 multiple sclerosis 29.5 TNF IL6 IL1B CLDN11
37 viral encephalitis 29.5 TNF IL6 IL1B
38 typhoid fever 29.5 TNF IL6 IL1B
39 gastroenteritis 29.5 TNF IL6 IL1B
40 chlamydia 29.5 TNF TLR2 IL6 IL1B HSPD1
41 osteomyelitis 29.4 TNF IL6 IL1B
42 immune deficiency disease 29.4 TLR9 CFH CD40LG
43 adult respiratory distress syndrome 29.4 TNF IL6 C4A
44 viral hepatitis 29.3 TNF TLR9 TLR2
45 meningitis 29.3 TNF TLR9 TLR2 IL6 IL1B
46 gingivitis 29.3 TNF TLR2 IL6 IL1B
47 lupus erythematosus 29.3 TNF CD40LG C4A C3
48 toxic shock syndrome 29.3 TNF TLR2 IL6 IL1B
49 chagas disease 29.3 TNF TLR2 IL6 IL1B
50 inflammatory bowel disease 29.2 TNF TLR2 IL6 IL1B

Graphical network of the top 20 diseases related to Lyme Disease:



Diseases related to Lyme Disease

Symptoms & Phenotypes for Lyme Disease

Human phenotypes related to Lyme Disease:

59 32 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
2 cranial nerve paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006824
3 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
4 meningitis 59 32 frequent (33%) Frequent (79-30%) HP:0001287
5 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
6 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
7 encephalitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002383
8 photophobia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000613
9 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
10 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
11 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
12 atrioventricular block 59 32 occasional (7.5%) Occasional (29-5%) HP:0001678
13 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
14 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
15 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
16 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
17 amaurosis fugax 59 32 occasional (7.5%) Occasional (29-5%) HP:0100576
18 headache 59 32 occasional (7.5%) Occasional (29-5%) HP:0002315
19 uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000554
20 insomnia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100785
21 skin nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0200036
22 dermal atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0004334
23 behavioral abnormality 59 Occasional (29-5%)
24 peripheral neuropathy 59 Occasional (29-5%)

Symptoms:

12
  • fever
  • fatigue
  • headache
  • skin rash called erythema migrans

UMLS symptoms related to Lyme Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Lyme Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 C3 C4A CFHR1 CLDN11 HSPD1 TLR1

MGI Mouse Phenotypes related to Lyme Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 C3 CD40LG CFH IL1B IL6 TLR1
2 immune system MP:0005387 10.06 C3 CD40LG CFH IL1B IL6 TLR1
3 mortality/aging MP:0010768 10 C3 CD40LG CFH HSPD1 IL1B IL6
4 nervous system MP:0003631 9.85 C3 CD40LG CFH CLDN11 HSPD1 IL1B
5 renal/urinary system MP:0005367 9.5 C3 CD40LG CFH IL6 TLR2 TLR7
6 reproductive system MP:0005389 9.23 C3 CD40LG CLDN11 HSPD1 IL6 TLR6

Drugs & Therapeutics for Lyme Disease

Drugs for Lyme Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
2
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
3
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Hydroxychloroquine Approved Phase 4 118-42-3 3652
6
Azithromycin Approved Phase 4 83905-01-5 447043 55185
7
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
13
Cortisone Experimental Phase 4 53-06-5 222786
14 Anti-Bacterial Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Antitubercular Agents Phase 4
17 Antibiotics, Antitubercular Phase 4
18 penicillins Phase 4
19 Antiviral Agents Phase 4
20 cefuroxime axetil Phase 4
21 Cytochrome P-450 CYP3A Inhibitors Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 valacyclovir Phase 4
24 Erythromycin Ethylsuccinate Phase 4
25 Erythromycin stearate Phase 4
26 Erythromycin Estolate Phase 4
27 Antiemetics Phase 4
28 Gastrointestinal Agents Phase 4
29 Peripheral Nervous System Agents Phase 4
30 Autonomic Agents Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Hormone Antagonists Phase 4
33 glucocorticoids Phase 4
34 Neuroprotective Agents Phase 4
35 Hormones Phase 4
36 Methylprednisolone Acetate Phase 4
37 Protective Agents Phase 4
38 Antineoplastic Agents, Hormonal Phase 4
39 Prednisolone acetate Phase 4
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
41
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
42
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
43
Acetaminophen Approved Phase 3 103-90-2 1983
44
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
45
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
46 Antiparasitic Agents Phase 2, Phase 3
47 Antimalarials Phase 2, Phase 3
48 Antiprotozoal Agents Phase 2, Phase 3
49 PENTA Phase 3
50 Antipyretics Phase 3

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment Completed NCT01635530 Phase 4 Doxycycline;Ceftriaxone
2 Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline. Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
3 Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome. Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
4 Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease Completed NCT01207739 Phase 4 Doxycycline;Clarithromycin and hydroxychloroquine;Placebo
5 A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy Completed NCT00510263 Phase 4 Prednisolone + placebo;Valaciclovir + placebo;Prednisolone + valaciclovir;Placebo + placebo
6 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
7 The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison Completed NCT00138801 Phase 3 Ceftriaxone;Doxycycline
10 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease Completed NCT00001101 Phase 3 ceftriaxone;doxycycline
11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease Completed NCT00000938 Phase 3 ceftriaxone;doxycycline
12 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
13 A Controlled Trial of a Primary and Secondary Program for Lyme Disease Completed NCT00000432 Phase 3
14 Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever Completed NCT00237016 Phase 2, Phase 3 doxycycline treatment
15 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial Enrolling by invitation NCT02553473 Phase 3 Doxycycline;Placebo
16 Symptomatic Management of Lyme Arthritis Not yet recruiting NCT04038346 Phase 3 Naproxen;Acetaminophen
17 Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Terminated NCT00958139 Phase 3
18 IV Ceftriaxone for Refractory Psychosis: a Controlled Trial Unknown status NCT00591318 Phase 1, Phase 2 ceftriaxone;Normal Saline
19 PET and MRI Imaging of Persistent Lyme Encephalopathy Completed NCT00037479 Phase 2 ceftriaxone
20 Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years Completed NCT01504347 Phase 1, Phase 2
21 A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers Completed NCT01243008 Phase 1, Phase 2 Application of SHB001
22 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Completed NCT01617083 Phase 2 Azithromycin;Placebo
23 Alternative Schedule Study For VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged 18 To 65 Years - A Randomized, Controlled, Observer-Blind Phase 2 Study Recruiting NCT03970733 Phase 2
24 Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study. Recruiting NCT03769194 Phase 2
25 Xenodiagnosis After Antibiotic Treatment for Lyme Disease - Phase II Study Recruiting NCT02446626 Phase 1, Phase 2 Xenodiagnosis
26 Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease Not yet recruiting NCT03891667 Phase 1, Phase 2 Disulfiram 500 MG
27 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years Completed NCT03010228 Phase 1
28 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
29 Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count. Unknown status NCT00942006 doxycycline;ceftriaxone
30 Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans Unknown status NCT01163994 ceftriaxone;doxycycline
31 A School-Based Intervention to Reduce Lyme Disease Unknown status NCT00594997
32 Meditation and Stretching for Post Treatment Lyme Disease Syndrome Unknown status NCT02344537
33 Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous Unknown status NCT02162992
34 Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome Unknown status NCT02687165 Milnacipran and D-cycloserine
35 Clinical Course, Serologic Response and Long-term Outcome in Elderly Patients With Early Lyme Borreliosis Completed NCT03371563 Antibiotics
36 Doxycycline in Therapy of Erythema Migrans - do the Accompanying Symptoms Influence the Outcome? Completed NCT01475708 Doxycycline
37 The Phenomenon of "Chronic Lyme"; an Observational Study Completed NCT01151150
38 Comparison of Two Culture Media for Cultivation of Borrelia Burgdorferi Sensu Lato Completed NCT02145754
39 Duration of Antibiotic Treatment of Erythema Migrans. A Randomized Clinical Trial. Completed NCT00910715 doxycycline;doxycycline;placebo
40 Inflammatory Responses in Borrelia Afzelii Culture Positive Patients With Early Disseminated or Early Localized Lyme Borreliosis Completed NCT03980015
41 Tick-Borne Encephalitis Virus and Lyme Borreliae Causing Coillness, Coinfection, or Just Coincidence. A Prospective Observational Study Completed NCT03958058 Anti-borrelial antibiotic therapy
42 Analysis of Erythema Migrans Lesions Completed NCT00132327
43 Searching for Persistence of Infection in Lyme Disease Completed NCT01143558 Early Phase 1
44 Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study Completed NCT01205464 Doxycycline;Placebo
45 Sofia 2 Lyme FIA Whole Blood Clinical Study Completed NCT03238274
46 Microbiologic Findings of Acute Facial Palsy in Children Completed NCT01537952
47 Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375 Completed NCT00034086 Lopinavir/Ritonavir;Lamivudine/Zidovudine;Tenofovir disoproxil fumarate;Lamivudine;Stavudine;Zidovudine;Didanosine
48 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
49 Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis Completed NCT02404974
50 Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis Recruiting NCT00910533 ceftriaxone

Search NIH Clinical Center for Lyme Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amoxicillin
Cefixime
Cefotaxime
Ceftriaxone
Cefuroxime
Clarithromycin

Cochrane evidence based reviews: lyme disease

Genetic Tests for Lyme Disease

Anatomical Context for Lyme Disease

MalaCards organs/tissues related to Lyme Disease:

41
Testes, Skin, Heart, Eye, T Cells, B Cells, Brain

Publications for Lyme Disease

Articles related to Lyme Disease:

(show top 50) (show all 10015)
# Title Authors PMID Year
1
Postoperative Lyme Arthritis in the Orthopaedic Patient. 38 17
31136727 2019
2
Extensive meningeal enhancement in acute central nervous system Lyme: Case series and review of literature. 38 17
30952554 2019
3
Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters. 38 17
31097026 2019
4
Functional characterization of Borrelia spielmanii outer surface proteins that interact with distinct members of the human factor H protein family and with plasminogen. 9 38
19858303 2010
5
Complement factor H binding by different Lyme disease and relapsing fever Borrelia in animals and human. 9 38
19604355 2009
6
Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov. 9 38
18706858 2009
7
Prospective study of serologic tests for lyme disease. 9 38
18532885 2008
8
Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC. 9 38
18417666 2008
9
Subacute transverse myelitis with Lyme profile dissociation. 9 38
19675732 2008
10
Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. 9 38
18248762 2008
11
Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi. 9 38
17160605 2006
12
Evidence that the BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. 9 38
16622245 2006
13
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. 9 38
16479520 2006
14
TLR2 expression in relation to IL-6 and IL-1beta and their natural regulators production by PMN and PBMC in patients with Lyme disease. 9 38
16864901 2006
15
Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. 9 38
16081885 2005
16
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. 9 38
16081826 2005
17
Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. 9 38
15939749 2005
18
[Effect of rhIL-15 on TLR2 expression and apoptosis of PMN from patients with Lyme disease]. 9 38
16130298 2005
19
Concentrations of macrophage inflammatory proteins MIP-1alpha and MIP-1beta and interleukin 8 (il-8) in lyme borreliosis. 9 38
15597225 2004
20
C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. 9 38
12853388 2003
21
Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. 9 38
12695997 2003
22
[Concentration of macrophage inflammatory proteins MIP-1 alpha and MIP-1 beta and interleukin 8 in erythema migrants]. 9 38
12362660 2002
23
[Lyme borreliosis--incidence of serum anti-myelin antibodies]. 9 38
11987581 2002
24
Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A. 9 38
11825956 2002
25
Recombinant flagellin A proteins from Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii in serodiagnosis of Lyme borreliosis. 9 38
11682523 2001
26
Recognition of multiple antibody epitopes throughout Borrelia burgdorferi p66, a candidate adhesin, in patients with early or late manifestations of Lyme disease. 9 38
11179382 2001
27
Downregulation of class II molecules on epidermal Langerhans cells in Lyme borreliosis. 9 38
11069457 2000
28
Reduced specificity of combined IgM and IgG enzyme immunoassay testing for lyme borreliosis. 9 38
10898148 2000
29
Evidence of Dbps (decorin binding proteins) among European strains of Borrelia burgdorferi sensu lato and in the immune response of LB patient sera. 9 38
10650211 2000
30
Utility of laboratory testing in autoimmune inner ear disease. 9 38
10569401 1999
31
Adherence of Borrelia burgdorferi. Identification of critical lysine residues in DbpA required for decorin binding. 9 38
10473582 1999
32
The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early lyme disease is the flaA gene product. 9 38
9986810 1999
33
The dominant epitope of Borrelia garinii outer surface protein C recognized by sera from patients with neuroborreliosis has a surface-exposed conserved structural motif. 9 38
9712750 1998
34
Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis. 9 38
9665957 1998
35
Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates. 9 38
9620365 1998
36
Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. 9 38
9542898 1998
37
Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies. 9 38
9455892 1998
38
Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis. 9 38
9350727 1997
39
Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. 9 38
9259573 1997
40
Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis. 9 38
9041433 1997
41
Polymerase chain reaction detection of Lyme disease: correlation with clinical manifestations and serologic responses. 9 38
8623775 1996
42
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. 9 38
8740122 1996
43
Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis. 9 38
8788993 1996
44
Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease. 9 38
8567889 1995
45
The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications. 9 38
7664493 1995
46
A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease. 9 38
7642278 1995
47
Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. 9 38
7768602 1995
48
Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition. 9 38
9158807 1995
49
Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. 9 38
8039891 1994
50
Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. 9 38
8077398 1994

Variations for Lyme Disease

Expression for Lyme Disease

Search GEO for disease gene expression data for Lyme Disease.

Pathways for Lyme Disease

Pathways related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TNF TLR9 TLR7 TLR6 TLR2 TLR1
2
Show member pathways
13.38 TNF TLR9 TLR7 TLR6 TLR2 TLR1
3
Show member pathways
13.19 TNF TLR9 TLR7 TLR6 TLR2 TLR1
4
Show member pathways
13.12 TNF TLR9 TLR7 TLR6 TLR2 TLR1
5
Show member pathways
12.88 TNF IL6 IL1B HSPD1 CD40LG C4A
6
Show member pathways
12.68 TNF TLR9 TLR7 TLR6 TLR2 TLR1
7
Show member pathways
12.64 TNF TLR9 TLR7 TLR6 TLR2 TLR1
8 12.57 TNF TLR9 TLR7 TLR6 TLR2 TLR1
9
Show member pathways
12.55 TNF TLR2 IL6 IL1B
10
Show member pathways
12.54 TNF IL6 IL1B CD40LG
11
Show member pathways
12.41 TLR9 TLR7 TLR6 TLR2 TLR1
12
Show member pathways
12.32 TNF TLR2 IL6 IL1B
13
Show member pathways
12.32 TNF TLR9 TLR7 TLR6 TLR2 TLR1
14
Show member pathways
12.28 TNF TLR2 IL1B CD40LG C3
15
Show member pathways
12.22 TNF TLR2 IL6 IL1B
16
Show member pathways
12.22 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
17
Show member pathways
12.2 TNF TLR9 IL6 IL1B
18 12.2 TNF IL6 IL1B HSPD1 C4A
19 12.19 TNF TLR9 TLR7 TLR6 TLR2 TLR1
20
Show member pathways
12.09 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
21
Show member pathways
11.98 TNF TLR9 TLR7 TLR6 TLR2 TLR1
22 11.97 TNF IL6 IL1B
23
Show member pathways
11.97 TNF TLR6 TLR2 TLR1 IL6 IL1B
24 11.94 TNF IL6 IL1B
25 11.94 TNF TLR2 IL6 IL1B
26 11.93 TNF IL6 IL1B
27
Show member pathways
11.91 CFH C4A C3
28 11.89 TNF TLR2 IL6 IL1B
29 11.88 TNF IL6 IL1B
30 11.88 TNF IL1B CD40LG
31 11.88 TLR9 TLR7 TLR6 TLR2 TLR1 C3
32 11.86 TNF IL6 IL1B
33 11.84 CFH C4A C3
34 11.84 TNF IL6 IL1B C4A C3
35 11.81 TNF TLR9 TLR7 IL6 IL1B
36 11.72 TNF IL6 IL1B
37
Show member pathways
11.71 TNF IL6 IL1B CD40LG
38
Show member pathways
11.67 TNF TLR9 TLR7 TLR6 TLR2 TLR1
39 11.66 TNF IL6 IL1B
41 11.59 TNF TLR2 IL6 IL1B HSPD1 C3
42 11.54 TNF IL6 IL1B
43 11.53 TNF TLR2 IL1B
44 11.53 TNF TLR9 TLR6 TLR2 TLR1 IL6
45 11.49 TNF IL6 IL1B
46 11.44 TNF TLR9 IL6 IL1B
47 11.42 TNF TLR9 TLR2 IL6 IL1B CD40LG
48 11.37 TNF IL6 IL1B
49 11.33 TNF IL6 IL1B
50 11.31 TNF IL6 IL1B

GO Terms for Lyme Disease

Cellular components related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.8 TLR9 TLR7 TLR6 TLR2 TLR1 IL1B
2 extracellular space GO:0005615 9.61 TNF IL6 IL1B HSPD1 CFHR1 CFH
3 phagocytic vesicle membrane GO:0030670 9.58 TLR6 TLR2 TLR1
4 blood microparticle GO:0072562 9.56 CFHR1 CFH C4A C3
5 endolysosome membrane GO:0036020 9.48 TLR9 TLR7
6 early phagosome GO:0032009 9.43 TLR9 TLR7
7 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1
8 membrane raft GO:0045121 8.92 TNF TLR6 TLR2 TLR1
9 plasma membrane GO:0005886 10.2 TNF TLR9 TLR7 TLR6 TLR2 TLR1
10 extracellular region GO:0005576 10.02 TNF TLR9 IL6 IL1B CFHR1 CFH

Biological processes related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 TNF TLR9 TLR7 TLR6 TLR2 TLR1
2 regulation of complement activation GO:0030449 9.94 CFHR1 CFH C4A C3
3 complement activation GO:0006956 9.93 CFHR1 CFH C4A C3
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 TNF IL6 IL1B
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF TLR9 TLR6 TLR2 IL6 IL1B
6 defense response to Gram-positive bacterium GO:0050830 9.9 TNF TLR2 IL6
7 positive regulation of JNK cascade GO:0046330 9.9 TNF TLR9 IL1B
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TNF TLR9 TLR7
9 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL1B CD40LG
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR9 TLR7 TLR2 IL1B
11 positive regulation of interferon-gamma production GO:0032729 9.87 TNF IL1B HSPD1
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF TLR6 IL1B
13 positive regulation of phagocytosis GO:0050766 9.85 TNF IL1B C3
14 positive regulation of interleukin-12 production GO:0032735 9.85 TLR9 TLR2 HSPD1 CD40LG
15 positive regulation of interleukin-10 production GO:0032733 9.84 TLR9 TLR2 HSPD1 CD40LG
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR2 IL1B
17 positive regulation of inflammatory response GO:0050729 9.83 TNF TLR9 TLR7 TLR2
18 toll-like receptor signaling pathway GO:0002224 9.83 TLR9 TLR7 TLR6 TLR2 TLR1
19 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
20 microglial cell activation GO:0001774 9.81 TNF TLR7 TLR6 TLR2
21 positive regulation of glial cell proliferation GO:0060252 9.8 TNF IL6 IL1B
22 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR9 TLR7 TLR2 IL1B
23 I-kappaB phosphorylation GO:0007252 9.78 TLR9 TLR7 TLR2
24 cell activation GO:0001775 9.77 TLR6 TLR2 TLR1
25 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.76 TNF TLR9 TLR7
26 regulation of cytokine secretion GO:0050707 9.76 TLR9 TLR6 TLR2 TLR1
27 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.75 TNF IL1B
28 positive regulation of JUN kinase activity GO:0043507 9.75 TNF TLR9 TLR6
29 positive regulation of macrophage activation GO:0043032 9.74 TLR6 HSPD1
30 negative regulation of lipid catabolic process GO:0050995 9.74 TNF IL1B
31 toll-like receptor 9 signaling pathway GO:0034162 9.74 TLR9 TLR7
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 TNF IL1B
33 positive regulation of interleukin-8 secretion GO:2000484 9.74 TLR2 TLR1
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B
35 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.74 TLR6 TLR1 IL1B
36 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.73 TLR9 TLR2
37 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.73 TLR9 TLR7
38 complement activation, alternative pathway GO:0006957 9.73 CFH C3
39 response to molecule of bacterial origin GO:0002237 9.73 TLR9 TLR2
40 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 TLR9 IL1B
41 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL6 IL1B
42 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
43 positive regulation of interferon-beta biosynthetic process GO:0045359 9.72 TLR9 TLR7
44 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B
45 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
46 positive regulation of chemokine production GO:0032722 9.72 TNF TLR9 TLR7 TLR2 IL6
47 positive regulation of apoptotic cell clearance GO:2000427 9.71 C4A C3
48 tumor necrosis factor production GO:0032640 9.71 TLR9 TLR2
49 regulation of immunoglobulin secretion GO:0051023 9.71 TNF CD40LG
50 positive regulation of interleukin-18 production GO:0032741 9.7 TLR9 TLR2

Molecular functions related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.67 TLR6 TLR2 TLR1 CFHR1
2 transmembrane signaling receptor activity GO:0004888 9.62 TLR9 TLR7 TLR6 TLR1
3 cytokine activity GO:0005125 9.56 TNF IL6 IL1B CD40LG
4 interleukin-1 receptor binding GO:0005149 9.43 TLR9 IL1B
5 siRNA binding GO:0035197 9.4 TLR9 TLR7
6 Toll-like receptor 2 binding GO:0035663 9.16 TLR6 TLR1
7 signaling pattern recognition receptor activity GO:0008329 9.13 TLR9 TLR7 TLR2
8 lipopeptide binding GO:0071723 8.8 TLR6 TLR2 TLR1

Sources for Lyme Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....